Which has better valuation and earnings, SOLV or MDLN?

Solventum has higher earnings, but lower revenue than Medline. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.62 $1.56B $8.16 9.52 Medline $28.43B 1.57 N/A N/A N/A

Is SOLV or MDLN more profitable?

Solventum has a net margin of 17.33% compared to Medline's net margin of 0.00%. Solventum's return on equity of 23.51% beat Medline's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% Medline N/A N/A N/A

Does the media refer more to SOLV or MDLN?

In the previous week, Medline had 3 more articles in the media than Solventum. MarketBeat recorded 9 mentions for Medline and 6 mentions for Solventum. Medline's average media sentiment score of 0.57 beat Solventum's score of 0.38 indicating that Medline is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medline 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GEHC or SOLV?

In the previous week, GE HealthCare Technologies had 9 more articles in the media than Solventum. MarketBeat recorded 15 mentions for GE HealthCare Technologies and 6 mentions for Solventum. GE HealthCare Technologies' average media sentiment score of 1.04 beat Solventum's score of 0.38 indicating that GE HealthCare Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SOLV or PHG?

Solventum currently has a consensus target price of $84.25, suggesting a potential upside of 8.43%. Given Solventum's stronger consensus rating and higher probable upside, equities analysts plainly believe Solventum is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solventum 1 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.50 Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor SOLV or PHG?

In the previous week, Solventum had 3 more articles in the media than Koninklijke Philips. MarketBeat recorded 6 mentions for Solventum and 3 mentions for Koninklijke Philips. Solventum's average media sentiment score of 0.38 beat Koninklijke Philips' score of 0.20 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ZBH or SOLV?

Solventum has higher revenue and earnings than Zimmer Biomet. Solventum is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zimmer Biomet $8.23B 2.00 $705.20M $3.85 22.05 Solventum $8.33B 1.62 $1.56B $8.16 9.52

Does the media prefer ZBH or SOLV?

In the previous week, Zimmer Biomet had 11 more articles in the media than Solventum. MarketBeat recorded 17 mentions for Zimmer Biomet and 6 mentions for Solventum. Zimmer Biomet's average media sentiment score of 1.05 beat Solventum's score of 0.38 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 11 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, SNN or SOLV?

Solventum has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.07 $625M N/A N/A Solventum $8.33B 1.62 $1.56B $8.16 9.52

Does the media prefer SNN or SOLV?

In the previous week, Solventum had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for Solventum and 1 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 0.38 beat Smith & Nephew SNATS's score of 0.00 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solventum 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Solventum (SOLV) Competitors

$77.70 +1.27 (+1.66%)

As of 12:46 PM Eastern

Compare

SOLV vs. MDLN, GEHC, PHG, ZBH, and SNN

Should you buy Solventum stock or one of its competitors? MarketBeat compares Solventum with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solventum include Medline (MDLN), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), and Smith & Nephew SNATS (SNN). These companies are all part of the "medical equipment" industry.

How does Solventum compare to Medline?

Solventum (NYSE:SOLV) and Medline (NASDAQ:MDLN) are both large-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Solventum currently has a consensus price target of $84.25, suggesting a potential upside of 8.43%. Medline has a consensus price target of $50.54, suggesting a potential upside of 48.38%. Given Medline's stronger consensus rating and higher possible upside, analysts clearly believe Medline is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79

In the previous week, Medline had 3 more articles in the media than Solventum. MarketBeat recorded 9 mentions for Medline and 6 mentions for Solventum. Medline's average media sentiment score of 0.57 beat Solventum's score of 0.38 indicating that Medline is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medline	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has higher earnings, but lower revenue than Medline.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.62	$1.56B	$8.16	9.52
Medline	$28.43B	1.57	N/A	N/A	N/A

Solventum has a net margin of 17.33% compared to Medline's net margin of 0.00%. Solventum's return on equity of 23.51% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Medline	N/A	N/A	N/A

Summary

Medline beats Solventum on 7 of the 11 factors compared between the two stocks.

How does Solventum compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Solventum has a net margin of 17.33% compared to GE HealthCare Technologies' net margin of 9.10%. Solventum's return on equity of 23.51% beat GE HealthCare Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.10%	20.46%	5.73%
Solventum	17.33%	23.51%	7.63%

82.1% of GE HealthCare Technologies shares are held by institutional investors. 0.4% of GE HealthCare Technologies shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

GE HealthCare Technologies has higher revenue and earnings than Solventum. Solventum is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.98B	1.34	$2.08B	$4.18	14.74
Solventum	$8.33B	1.62	$1.56B	$8.16	9.52

GE HealthCare Technologies has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Solventum has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

In the previous week, GE HealthCare Technologies had 9 more articles in the media than Solventum. MarketBeat recorded 15 mentions for GE HealthCare Technologies and 6 mentions for Solventum. GE HealthCare Technologies' average media sentiment score of 1.04 beat Solventum's score of 0.38 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GE HealthCare Technologies presently has a consensus price target of $80.21, suggesting a potential upside of 30.19%. Solventum has a consensus price target of $84.25, suggesting a potential upside of 8.43%. Given GE HealthCare Technologies' higher probable upside, analysts clearly believe GE HealthCare Technologies is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	0 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

GE HealthCare Technologies beats Solventum on 10 of the 15 factors compared between the two stocks.

How does Solventum compare to Koninklijke Philips?

Solventum (NYSE:SOLV) and Koninklijke Philips (NYSE:PHG) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

13.7% of Koninklijke Philips shares are owned by institutional investors. 0.2% of Solventum shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Solventum has a net margin of 17.33% compared to Koninklijke Philips' net margin of 5.49%. Solventum's return on equity of 23.51% beat Koninklijke Philips' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Koninklijke Philips	5.49%	13.51%	5.48%

Solventum has higher earnings, but lower revenue than Koninklijke Philips. Solventum is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.62	$1.56B	$8.16	9.52
Koninklijke Philips	$17.64B	1.38	$1.01B	$1.17	21.60

Solventum has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Solventum currently has a consensus target price of $84.25, suggesting a potential upside of 8.43%. Given Solventum's stronger consensus rating and higher probable upside, equities analysts plainly believe Solventum is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Solventum had 3 more articles in the media than Koninklijke Philips. MarketBeat recorded 6 mentions for Solventum and 3 mentions for Koninklijke Philips. Solventum's average media sentiment score of 0.38 beat Koninklijke Philips' score of 0.20 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Solventum beats Koninklijke Philips on 12 of the 16 factors compared between the two stocks.

How does Solventum compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by company insiders. Comparatively, 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Solventum has a net margin of 17.33% compared to Zimmer Biomet's net margin of 9.05%. Solventum's return on equity of 23.51% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Solventum	17.33%	23.51%	7.63%

Zimmer Biomet currently has a consensus price target of $102.70, suggesting a potential upside of 20.97%. Solventum has a consensus price target of $84.25, suggesting a potential upside of 8.43%. Given Zimmer Biomet's higher possible upside, equities analysts plainly believe Zimmer Biomet is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Zimmer Biomet has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Solventum has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Solventum has higher revenue and earnings than Zimmer Biomet. Solventum is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	2.00	$705.20M	$3.85	22.05
Solventum	$8.33B	1.62	$1.56B	$8.16	9.52

In the previous week, Zimmer Biomet had 11 more articles in the media than Solventum. MarketBeat recorded 17 mentions for Zimmer Biomet and 6 mentions for Solventum. Zimmer Biomet's average media sentiment score of 1.05 beat Solventum's score of 0.38 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	11 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Solventum beats Zimmer Biomet on 9 of the 17 factors compared between the two stocks.

How does Solventum compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by insiders. Comparatively, 0.2% of Solventum shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Smith & Nephew SNATS presently has a consensus target price of $30.93, suggesting a potential upside of 3.57%. Solventum has a consensus target price of $84.25, suggesting a potential upside of 8.43%. Given Solventum's higher possible upside, analysts plainly believe Solventum is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Solventum had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for Solventum and 1 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 0.38 beat Smith & Nephew SNATS's score of 0.00 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solventum	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Smith & Nephew SNATS has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Solventum has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Solventum has a net margin of 17.33% compared to Smith & Nephew SNATS's net margin of 0.00%. Solventum's return on equity of 23.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Solventum	17.33%	23.51%	7.63%

Solventum has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A
Solventum	$8.33B	1.62	$1.56B	$8.16	9.52

Summary

Solventum beats Smith & Nephew SNATS on 10 of the 14 factors compared between the two stocks.

Get Solventum News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SOLV vs. The Competition

Export

Metric	Solventum	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$13.46B	$8.52B	$6.26B	$23.11B
Dividend Yield	N/A	1.77%	2.69%	4.09%
P/E Ratio	9.52	22.12	22.37	31.03
Price / Sales	1.62	25.35	547.57	14.71
Price / Cash	8.44	90.05	42.31	24.78
Price / Book	2.67	5.00	9.79	4.68
Net Income	$1.56B	$178.24M	$3.56B	$1.07B
7 Day Performance	2.13%	-1.74%	-1.27%	-0.50%
1 Month Performance	16.35%	2.98%	3.58%	0.39%
1 Year Performance	4.67%	1.70%	27.13%	25.64%

Solventum Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SOLV Solventum	3.016 of 5 stars	$77.70 +1.7%	$84.25 +8.4%	+4.5%	$13.46B	$8.33B	9.52	20,000
MDLN Medline	3.7783 of 5 stars	$37.01 flat	$50.85 +37.4%	N/A	$48.62B	$28.43B	N/A	43,000	Analyst Forecast High Trading Volume
GEHC GE HealthCare Technologies	4.9421 of 5 stars	$64.23 flat	$80.21 +24.9%	-11.6%	$29.22B	$20.63B	15.37	54,000
PHG Koninklijke Philips	2.4442 of 5 stars	$26.96 +0.0%	N/A	+11.5%	$25.95B	$20.17B	23.10	65,340
ZBH Zimmer Biomet	4.487 of 5 stars	$85.41 -0.1%	$102.80 +20.4%	-8.1%	$16.54B	$8.23B	22.19	17,000	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SOLV) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solventum (SOLV) Competitors

SOLV vs. MDLN, GEHC, PHG, ZBH, and SNN

How does Solventum compare to Medline?

Summary

How does Solventum compare to GE HealthCare Technologies?

Summary

How does Solventum compare to Koninklijke Philips?

Summary

How does Solventum compare to Zimmer Biomet?

Summary

How does Solventum compare to Smith & Nephew SNATS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOLV vs. The Competition

Solventum Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solventum (SOLV) Competitors

SOLV vs. MDLN, GEHC, PHG, ZBH, and SNN

How does Solventum compare to Medline?

Do analysts rate SOLV or MDLN?

Does the media refer more to SOLV or MDLN?

Which has better valuation and earnings, SOLV or MDLN?

Is SOLV or MDLN more profitable?

Summary

How does Solventum compare to GE HealthCare Technologies?

Is GEHC or SOLV more profitable?

Do insiders and institutionals have more ownership in GEHC or SOLV?

Which has better earnings and valuation, GEHC or SOLV?

Which has more risk and volatility, GEHC or SOLV?

Does the media prefer GEHC or SOLV?

Do analysts recommend GEHC or SOLV?

Summary

How does Solventum compare to Koninklijke Philips?

Do institutionals & insiders have more ownership in SOLV or PHG?

Is SOLV or PHG more profitable?

Which has higher valuation and earnings, SOLV or PHG?

Which has more volatility and risk, SOLV or PHG?

Do analysts recommend SOLV or PHG?

Does the media favor SOLV or PHG?

Summary

How does Solventum compare to Zimmer Biomet?

Do institutionals and insiders have more ownership in ZBH or SOLV?

Is ZBH or SOLV more profitable?

Do analysts rate ZBH or SOLV?

Which has more volatility and risk, ZBH or SOLV?

Which has preferable earnings and valuation, ZBH or SOLV?

Does the media prefer ZBH or SOLV?

Summary

How does Solventum compare to Smith & Nephew SNATS?

Do institutionals & insiders have more ownership in SNN or SOLV?

Do analysts prefer SNN or SOLV?

Does the media prefer SNN or SOLV?

Which has more risk and volatility, SNN or SOLV?

Is SNN or SOLV more profitable?

Which has preferable valuation & earnings, SNN or SOLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOLV vs. The Competition

Solventum Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools